2M BioTech, Calico deal

2M BioTech granted Calico exclusive, worldwide rights to develop and commercialize a portfolio of modulators of nicotinamide phosphoribosyl transferase ( NamPRT; NAMPT). The deal includes 2M's preclinical P7C3 program, which has been focused on neurodegenerative diseases, including Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). 2M said Calico, which is led by CEO Arthur Levinson and was launched last year by Google Inc. (NASDAQ:GOOG, Mountain View, Calif.), is evaluating which indications it will pursue for Phase I testing. 2M will receive an undisclosed upfront payment and is eligible for undisclosed milestones and royalties. Calico also will fund research laboratories to support the program. ...